AOD-9604 vs Tesamorelin
Verdict: Tesamorelin has the evidence: an FDA approval and trials showing 15–18% visceral fat reduction. AOD-9604 has the theory — a GH fragment meant to burn fat without GH's other effects — but its phase 2 trials in the 2000s failed to show meaningful weight loss and development stopped. Tesamorelin costs more and needs IGF-1 monitoring; AOD-9604 is cheaper and very well tolerated but its fat-loss claim rests on animal data. For stubborn visceral fat with a budget, tesamorelin.
Side by side
| AOD-9604 | Tesamorelin | |
|---|---|---|
| Typical dose | 250 mcg–500 mcg | 1 mg–2 mg |
| Frequency | daily, often fasted | daily |
| Administration | subcutaneous injection | subcutaneous injection |
| Common vials | 2 mg, 5 mg | 5 mg, 10 mg |
| Typical mix | 5 mg + 2 ml water | 5 mg + 2 ml water |
| Units for typical dose | 12 units (300 mcg) | 80 units (2 mg) |
Two routes to fat loss
Tesamorelin is a GHRH analog: it makes the pituitary release more growth hormone, which in turn mobilizes fat, with visceral fat being the most responsive depot. AOD-9604 is the C-terminal fragment of GH itself (amino acids 177–191) — the region thought to carry GH's lipolytic effect — designed to act on fat cells directly without raising IGF-1 or affecting glucose.
What the trials showed
Tesamorelin: multiple phase 3 trials in HIV lipodystrophy with ~15–18% reductions in visceral adipose tissue at 26 weeks, plus liver-fat reductions in later studies. AOD-9604: Metabolic Pharmaceuticals' phase 2b obesity trial (2007) found no clinically meaningful weight loss versus placebo; the program was discontinued and the compound later found a second life as a cosmetic and research peptide.
Dosing and tolerability
Tesamorelin: 1–2 mg daily subcutaneous; side effects include joint pain, fluid retention, injection-site reactions and IGF-1 elevation. AOD-9604: 250–500 mcg daily, subcutaneous or oral; side effects in trials were essentially placebo-level, which is its genuine strength.
Can you stack them?
Both appear in fat-loss stacks with a GH secretagogue pair, and AOD-9604 is often added to tesamorelin or CJC/ipamorelin protocols as a low-risk adjunct. There is no trial evidence for any of these combinations.
More comparisons
Educational comparison based on commonly published research protocols — not medical advice or an endorsement of any compound.